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ABSTRACT: Nonsmall-cell lung cancer (NSCLC) is the most common type of lung
cancer, with a dismal prognosis. NSCLC is a highly vascularized tumor, and chemotherapy is
often hampered by the development of angiogenesis. Therefore, suppression of angiogenesis
is considered a potential treatment approach. Tannic acid (TA), a natural polyphenol, has
been demonstrated to have anticancer properties in a variety of cancers; however, its
angiogenic properties have yet to be studied. Hence, in the current study, we investigated the
antiproliferative and antiangiogenic eﬀects of TA on NSCLC cells. The (3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
(MTS) assay revealed that TA induced a dose- and time-dependent decrease in the
proliferation of A549 and H1299 cells. However, TA had no signiﬁcant toxicity eﬀects on
human bronchial epithelial cells. Clonogenicity assay revealed that TA suppressed colony
formation ability in NSCLC cells in a dose-dependent manner. The anti-invasiveness and
antimigratory potential of TA were conﬁrmed by Matrigel and Boyden chamber studies,
respectively. Importantly, TA also decreased the ability of human umbilical vein endothelial cells (HUVEC) to form tube-like
networks, demonstrating its antiangiogenic properties. Extracellular vascular endothelial growth factor (VEGF) release was reduced
in TA-treated cells compared to that in control cells, as measured by the enzyme-linked immunosorbent assay (ELISA). Overall,
these results demonstrate that TA can induce antiproliferative and antiangiogenic eﬀects against NSCLC.

1. INTRODUCTION
Lung cancer (LC) is the most common and fatal malignancy in
men and women in the United States. For the year 2022, the
American Cancer Society estimated that about 236,740 new
cancer cases and 130,180 deaths will occur due to LC in the
United States.1 It accounts for 12.5% of all cancer diagnoses
and 21% of total cancer-related mortality. Nonsmall-cell lung
cancer (NSCLC) and small-cell lung cancer (SCLC) are two
diﬀerent types of cancer, which diﬀer in their histology,
patterns of occurrence, and prognoses.2 NSCLC is the most
common LC, accounting for 85 percent of all cases. Despite
recent advancements in standard treatment approaches such as
surgery, radiation, chemotherapy, and targeted therapy, the
survival rate remains low.
Angiogenesis, like that of other solid tumors, is considered as
a critical phase in the advancement of lung malignancies.
Angiogenesis is a process of blood vessel formation in tumor
microenvironments and represents one of the hallmarks of
cancer growth, proliferation, metastasis, and chemoresistance.3
These newly formed blood vessel networks are responsible for
carrying nutrients and oxygen to the tumor cells, and they
undergo rapid development and serve as channels to promote
metastasis of cancer cells to distant organs.4,5 The lungs are a
highly vascularized organ, and studies have shown that NSCLC
© 2022 The Authors. Published by
American Chemical Society

development and progression are closely linked to major
changes in the blood vessel system; thus, inhibiting angiogenesis is a promising approach for NSCLC treatment.6
Angiogenesis inhibitors such as bevacizumab and other
tyrosine kinase inhibitors are used to treat lung cancer.
Bevacizumab, a potent vascular endothelial growth factor
(VEGF)-humanized monoclonal antibody, blocks/inhibits
angiogenesis and neovascularization.7 The VGEF is a critical
element in cancer angiogenesis, where an induction in VGEF
activation is responsible to boost the new blood vessel
formation and enhance the development of fresh vasculature
networks to be able to eﬃciently supply the oxygen and
nutrient stock to the constantly growing tumor.8 Notably, the
VEGF is also a potent stimulator of proliferation and
migration; it induces the expression of the metalloproteinases
(MMPs). Numerous studies have reported that the overexpression of the VEGF intensiﬁes the tumor growth and
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Figure 1. Tannic acid exhibits NSCLC cell-speciﬁc cytotoxicity. (A) Chemical structure of tannic acid. (B) Normal human bronchial epithelium
cell line (BEAS-2B) and NSCLC (A549 and H1299) cells were treated with diﬀerent concentrations of TA (0−40 μM) and incubated for 48 and
72 h. Cell proliferation assay was evaluated after addition of the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium) (MTS) reagent. Data represent means ± SEM, n = 3. A table representing the IC50 of TA in NSCLC cells at 48 and 72 h. (C) Cell
(BEAS-2B, A549 and H1299) morphology changes were studied using an inverted microscope.

metastasis by expanding the vasculature network.9 Bevacizumab has also been studied in SCLC, with varying results in
both conﬁned and prolonged disease. When paired with ﬁrstline chemotherapy, bevacizumab increased progression-free
survival but not overall survival.10 As a result, ﬁnding eﬀective
antilung cancer drugs, especially those generated from natural
resources, is a viable strategy to increase patient compliance
and survival rates.
Tannic acid (TA, C76H52O46) (Figure 1A), a naturally
occurring water-soluble polyphenolic extract, has been

approved as a safe compound by the US Food and Drug
Administration (FDA), which made it a safe excipient/active
additive in food, drink, and pharmaceutical formulations.11−13
TA is abundantly available, as it is commonly present in plant
leaves (e.g., green tea), fruit skins, vegetables, nuts, red wine,
coﬀee, and wood bark. TA (penta-m-digalloyl glucose)
contains a unique hydrolyzable structure of tannin with a
glucose moiety core.14 The hydroxyl groups of this glucose are
esteriﬁed with ﬁve digallic acids.15 TA exhibits antioxidant,
antimicrobial, antiviral, and anti-inﬂammatory properties.16
23940
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Mannheim, Germany) was performed to determine the cell
viability.29 The assay was carried out in 96-well microplates.
Each of the A549, H1299, and BEAS-2B cell lines (5 × 103
cells/well) was seeded in their respective media and left
overnight for adhesion. On the following day, cells were
treated with diﬀerent concentrations of TA (1.25, 2.5, 5, 10,
20, and 40 μM). After 48 and 72 h of treatment, 20 μL of the
MTS solution was added to each well and incubated at 37 °C
and 5% CO2. The absorbance of each well was measured using
a microplate reader (Cytation 5, BioTek Instruments,
Winooski, VT) at 490 nm according to the manufacturer’s
instructions. The cell viability of treated cells was normalized
to absorbance readings in untreated control cells (considered
to have 100% viability). The concentration required for 50%
cell growth inhibition (IC50) was calculated using GraphPad
Prism 6.07 software (Dotmatics, San Diego, CA).
2.3. Colony Formation. The impact of TA on inhibiting
the clonogenicity of NSCLC cells was tested by the colony
formation assay.29 The A549 and H1299 cells (500 cells/well)
were cultured in multi-well plates and were allowed to attach
and initiate the colonization for 48 h. Then, the medium was
replaced with a fresh one containing a varying concentration of
TA (2.5, 5, and 10 μM) alongside one without treatment for
the control and incubated further for 2 weeks. At the end of
the 14 days, colonies were ﬁxed with cold methanol and
stained using 0.05% crystal violet at room temperature. The
cell colonies were photographed utilizing a ChemiDoc MP
imaging system (Bio-Rad, Hercules, CA), and the number of
colonies was counted using publicly available ImageJ software
(www.imagej.nih.gov/ij/).
2.4. Cell Migration. The eﬀect of TA on NSCLC cell
mobility and migration was evaluated through Boyden’s
chamber assay and was utilized .29 In brief, the cells were
subjected to starvation by culturing them overnight in serumfree media and plated in the upper chambers of a 96-transwell
plate at 5 × 105 cells containing 20 μM TA concentration and
one with an equivalent amount of the phosphate-buﬀered
saline (PBS) as the control in the serum-free medium, while
lower chamber contains complete medium containing 10%
FBS. Cells were allowed to migrate toward the fetal bovine
serum (FBS) gradient for 24 h; then, the migrated cells were
ﬁxed with 4% paraformaldehyde for 45 min and stained with
0.05% crystal violet for 30 min at room temperature. The
migrated cells were imaged under a microscope (EVOS FL
microscopy (AMF4300, Life Technologies, Carlsbad, CA)).
2.5. Wound Healing. The eﬀect of TA on NSCLC cell’s
wound healing ability was assessed using a scratch assay.29
Brieﬂy, A549 and H1299 cells were cultured in 6-well plates
overnight at the density of 1 × 106 cells/well. When the degree
of fusion reached 80%, to create wounds, a 200 μL sterile
pipette tip was applied to create wounds on each well. After
rinsing the cells with PBS to wash out the debris, cells were
treated with 10 μM TA with an untreated well as a control, and
the extent of the treatment eﬀect was monitored till 72 h. The
residual of the wounds was closely observed and photographed
at 24 h intervals using an EVOS FL imaging system.
2.6. Cell Invasion. To analyze the eﬀect of TA on the
invasion potential of NSCLCs (A549 and H1299), BioCoat
Matrigel invasion chambers (BD Biosciences, Bedford, MA)
were utilized.21,29 The starved cells, as described above, were
distributed on the transwell inserts at a density of 3.5 × 104
and incubated with 20 μM TA and PBS (as control) for 24 h.
The cells that invaded to the lower chamber were ﬁxed with

TA’s broad range of bioactivities makes it a potent and viable
pharmaceutical additive molecule for various indications. We
anticipate that TA could eﬀectively modulate the tumor
biology of NSCLC by altering the angiogenesis processes.
The chemopreventive and anticancer eﬀects of TA have
been shown against various types of cancers such as breast,17,18
ovarian,19 and brain cancers.20 The literature supports that TA
is able to suppress cancer progression via inhibiting various
oncogenic signaling pathways.21−23 TA-induced apoptotic
eﬀects on FAS-overexpressed human breast cancer cells have
also been reported.24 TA modulates drug eﬄux and enhances
the cytotoxicity of chemotherapeutic agents in human
cholangiocarcinoma.25 TA is involved in reversing drug
resistance by inhibiting the ubiquitin−proteasome pathway,26
inhibiting ATP-binding cassette (ABC) transporters,27 and
downregulating P-glycoprotein (P-gp) and multidrug resistance (MDR) via downregulation of NF-κB and MAPK/ERK.28
A recent study in our laboratory has conﬁrmed TA-induced
endoplasmic reticulum stress-mediated apoptosis and lipid
metabolism in prostate cancer cells.29,30 TA has been shown to
have a potent tyrosine kinase activity.31 In lung cancer cells,
TA inhibits stemness by triggering caspase-dependent
mitochondria-mediated apoptosis.32
Tannic acid exhibits a selective CXCL12/CXCR4 antagonist, which suggests its antitumor and antiangiogenic
potential.33 To the best of our knowledge, TA’s inﬂuence on
angiogenesis via modulation of the VEGF secretion from
NSCLC remains largely unknown.29 Therefore, understanding
the response of NSCLC cells to a water-soluble natural
anticancer agent (TA) is a clinically unmet need. In addition,
revealing the underlying aspects of TA’s antiangiogenic eﬀects
and how it may alter the tumor biology holds great promise for
identifying new therapeutic targets for NSCLC in clinical
translation. Taken together, in this study, our goal is to
elucidate the eﬀect of TA on NSCLC cells. We will investigate
NSCLC cells that were incubated with diﬀerent concentrations
of TA. Outcomes were measured by characterizing cell
proliferation, invasiveness, apoptosis, VEGF secretion, and
angiogenesis in NSCLC cell lines.

2. MATERIALS AND METHODS
2.1. Materials, Reagents, and Cell Culture. All the
chemicals, solvents, reagents, and cell culture media were
purchased from Sigma-Aldrich Co. (St. Louis, MO) and Fisher
Scientiﬁc (Pittsburgh, PA) and used without further
puriﬁcation unless otherwise stated. Nonsmall-cell lung cancer
cell lines (A549 and H1299), a human normal bronchial
epithelial cell line (BEAS-2B), and human umbilical vein
endothelial cells (HUVEC) were purchased from American
Type Culture Collection (ATCC, Manassas, VA). The H1299,
A549, BEAS-2B, and HUVECs were cultured in Roswell Park
Memorial Institute-1640 (RPMI-1640), Dulbecco’s modiﬁed
Eagle medium (DMEM), bronchial epithelial cell growth
medium (BEGM), and endothelial cell medium-2 (EGM TM2). All media were supplemented with 10% fetal bovine serum
and 1% (w/v) penicillin−streptomycin. Cell lines were
maintained at 37 °C with a humidiﬁed atmosphere of 5%
CO2 in an incubator. Cell lines were regularly monitored for
their typical morphology and contamination under a microscope. These cells were trypsinized and seeded for in vitro
studies.
2.2. Cell Viability. The CellTiter 96 AQueous One
Solution Cell Proliferation Assay (MTS reagent, Promega,
23941
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solution control over two diﬀerent incubation times (48 and
72 h) was characterized. As shown in Figure 1B, TA
suppressed the growth of NSCLC cells in a dose-dependent
and time-responsive manner. IC50 values were calculated as
23.76 ± 1.17 and 10.69 ± 0.83 μM for the A549 cell line and
21.58 ± 1.12 and 7.136 ± 0.64 μM for the H1299 cell line, at
48 and 72 h, respectively. Both A549 and H1299 cells
demonstrated varied degrees of phenotypic alterations, such as
the loss of viable cells and blebbing, when treated with TA,
while control cells maintained their usual phenotype until the
treatment step was completed (Figure 1C).
3.2. Tannic Acid Suppresses the Clonogenic Potential
of NSCLC Cells. Enhanced clonogenic potential is a very
important characteristic of cancer growth and metastasis. The
clonogenic growth characteristic is necessary for the cancer
cells to establish a primary tumor and eventually metastasis.38
Therefore, the eﬀect of TA on the colony formation ability of
A549 and H1299 cells was determined on a long-term basis
(14 days) at various concentrations (2.5, 5, and 10 μM)
(Figure 2).

cold methanol for 30 min and were stained using crystal violet.
Invaded cells on membranes were imaged using EVOS FL
microscopy.
2.7. Bioinformatics Analysis. A total of 53 altered protein
targets of TA were manually curated from the literature and
standardized by authors. The protein−protein interaction
(PPI) network and pathway enrichment analyses were
obtained from the Kyoto Encyclopedia of Genes and Genomes
(KEGG) plugin of STRING databases. Cytoscape was used for
the construction of the ﬁnal PPI of TA-regulated proteins,
which was notiﬁed with the color gradient on the basis of the
bottleneck property of protein topology.34,35 The threedimensional (3D) structures of VEGFA (PDB ID: 5FV1),
CBP (PDB ID: 5J0D), and P300 (PDB ID: 6GYR) proteins
were retrieved from the RCSB protein databank, whereas the
3D structure of TA (PubChem CID: 16129778) was
constructed using Biovia Discovery Studio 20202. The
FireDock docking server was applied for the interaction
analysis between VEGFA, CBP, P300, and TA.36
2.8. Tube Forming Assay. The in vitro antiangiogenic
eﬀect of TA on HUVECs (with a passage number lower than
ﬁve) was analyzed by evaluating the extent of vascular
structure/tubular formation of cells.37 The 96-well plates
were ﬁlled with 50 μL of Matrigel (Becton, Dickinson and
Company) diluted with PBS (1:1) and placed in an incubator
at 37 °C for 1 h to be solidiﬁed. Then, HUVECs (1 × 104
cells/well) were incubated with a range of TA concentrations
(10, 15, 20, and 30 μM) and added to the Matrigel-coated
plates. After allowing vascular structure formation for 4 h at
37 °C in an incubator, the vascular-like structures/networks
were observed using an EVOS FL imaging system; a
quantiﬁcation of three random regions was assessed using
ImageJ software using an angiogenesis analyzer.
2.9. Enzyme-Linked Immunosorbent Assay. The
enzyme-linked immunosorbent assay (ELISA) was performed
to test the TA inﬂuence on the downregulation of the VEGF
protein expression on NSCLC. The A549 and H1299 cells
were cultured in 6-well plates at a density of 1 × 106 cells/well.
On the next day, the cells were treated with TA (5, 10, 20, and
30 μM) for 24, 48, and 72 h. Then, the supernatant media
were harvested and stored at −20 °C. A commercially available
VEGF Quantikine ELISA Kit-DVE00 (R&D Systems,
Minneapolis, MN) was used to measure the levels of the
VEGF, according to the manufacturer’s instructions.
2.10. Statistical analysis. All statistical analyses were
attempted using GraphPad Prism (Version 6.07, GraphPad
Software) to analyze the data. The results are described as the
means ± SEM of three individual sets of experiments. The
diﬀerence among the groups was estimated by Student’s t-test
or one-way analysis of variance (ANOVA). The level of
statistical signiﬁcance was set to *p < 0.01 and **p < 0.001.

Figure 2. Tannic acid treatment signiﬁcantly reduces the clonogenic
potential of NSCLC cells. The long-term antiproliferative eﬀects of
TA were evaluated in a colony formation assay. The colony formation
assay was performed on A549 and H1299 cells. The 500 cells were
seeded per well of a multi-well plate, and treatment with TA was done
at diﬀerent concentrations (0, 2.5, 5, and 10 μM) for 14 days. (A)
Colonies were stained with hematoxylin, and images were captured
using a phase-contrast microscope. Representative images of the
colony formation assay of A549 and H1299. (B) Number of colonies
are counted and plotted for A549 and H1299. Data represent
means ± SEM, n = 3. *p < 0.01, **p < 0.001.

3. RESULTS
3.1. Tannic Acid Inhibits the Proliferation of NSCLC
Cells. First, the cell viability assay was utilized to test a safe
concentration range of TA against the normal human bronchial
epithelium cell line (BEAS-2B). The tested concentrations
from 2.5 to 40 μM appear to be nontoxic to BEAS-2B cells in
48 and 72 h treatments (Figure 1B, blue color line graphs and
Figure 1C). At these concentrations, it was observed that there
is more than 90% of cell viability. Then, the potential
inhibitory eﬀect of TA on the proliferation of two NSCLC
(A549 and H1299) cells in this concentration range or vehicle

TA exhibited reduction of the number of visible and bigger
colonies in a dose-dependent manner (Figure 2A). The
quantitative analysis revealed that the percent number of cell
colonies was signiﬁcantly reduced with increasing TA
concentration. This eﬀect is similar in both A549 and H1299
cell lines (Figure 2B). Together, these results indicate that TA
suppresses the colony formation ability of the NSCLC.
23942
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the wound and ﬁll the gap to support the reduced migratory
capability (Figure 3B) was conﬁrmed by a wound healing
assay. The extent of the wound closure was maintained with
TA treatment, while the untreated-well wound was healed due
to the inherent migratory characteristics of NSCLC. Overall,
these results conﬁrm the antimigratory ability of TA on
NSCLC cells. In carcinogenic events, cancer cells disseminated
through blood or lymphatics to other sites via invasion.40,41 To
gain a better understanding of the anti-invasion ability of TA, a
transwell assay was performed on A549 and H1299 cells. The
number of invaded cells A549 and H1299 toward the FBS
gradient was markedly lower in the treatment group compared
to that in the control group (Figure 3C). These results
indicated that TA could be a promising adjuvant to inhibit the
invasion of NSCLC cells.
3.4. Bioinformatics Analysis. After pathway enrichment
and PPI analysis of the altered TA target protein dataset
(Figure 4), we found the involvement of numerous proteins in
diﬀerent types of cancers. In this enrichment analysis, we found
that around 35 proteins out of 53 proteins in the dataset follow
a category of cancer-related pathways (hsa05200) with the
highest FDR being 2.47E-39. These proteins include MAPK1,
NFKBIA, MMP2, TGFB1, NFKB1, CDKN1B, CDK4,
PDGFRB, CCNE1, WNT5A, RB1, EGFR, NOTCH1, BRAF,
BAX, BCL2L1, CYCS, CASP3, KLK3, GSK3B, CASP9, TCF7,
CTNNB1, FAS, STAT1, PTGS2, CASP7, MMP9, JAK2,
CXCL12, BCL2, CDKN1A, CXCR4, WNT8A, and VEGFA.
After carrying out network analysis, it was found that around
ﬁve top proteins have bottleneck features of more than two. In
between all these important proteins, CTNNB1 and VGFRA
were featured as the most important key regulatory proteins of
this TA-governed interactome. Among these two proteins, lung
cancer was clinically treated using angiogenesis inhibitors
which regulate VEGFA. Therefore, the TA inﬂuence on this
protein is considered in this investigation. VEGFA is also
spotted as an important key regulatory node of the TAgoverned interactome with a 78 score of degree and 0.33796
(its less than 0.5) score of clustering coeﬃcient. These
statistical connections show the importance of VEGFA in the
TA-governed interactome. The degree stands for the number
of physical or functional interactions of a node with other
nodes, and the clustering coeﬃcient represents the closeness of
nodes and neighbors; the clustering coeﬃcient also illustrates
that the network has a high number of nodes but holds a lesser
number of connections, so there are high chances of binding of
ligands such as tannic acid.34
After getting the probable target (VEGFA) of TA, docking
analysis was performed; the resultant TA docked perfectly with
VEGFA with −36.17 global binding energy (Figure 5A). On
the other hand, TA was also able to dock with CBP (Figure
5B) and P300 (Figure 5C) with global binding energies of
−34.24 and −59.99, respectively.
3.5. TA Inhibits In Vitro Tube Formation Activity.
Endothelial cell migration, invasion, adhesiveness, tube
assembly, and remodeling are footsteps of the new vessel
formation (angiogenesis).42 Angiogenesis is a highly regulated
process that involves the growth of new blood vessels from the
existing vasculature. This process plays an important role in
both normal developmental processes and numerous pathologies, ranging from wound healing, tumor growth, and
metastasis to inﬂammation and ocular diseases. Therefore, to
determine the physiological signiﬁcance of the changes in the

3.3. Tannic Acid Inhibits the Migration and Invasion
Potential of NSCLC Cells. Tumor cell metastasis is known as
a complex of events, which involves cell adhesion, extracellular
matrix (ECM) component degradation, and tumor cell
migration. Thus, blocking one or more of these steps is
required for antimetastatic therapy.39 The eﬀects of TA on
NSCLC’s invasion and migratory abilities were subsequently
assessed by performing the Boyden chamber assay (Figure 3).
The number of migrating cells after TA treatment was
evidently inhibited in A549 and H1299 cells compared with
that in the control (Figure 3A). The ability of the cells to heal

Figure 3. Tannic acid treatment minimizes the migration and invasion
ability of NSCLC cells. (A) Boyden chamber migration assay was
performed on NSCLC cells A549 and H1299. The cells were treated
with 0 and 20 μM concentrations for 18 h. After that, the cells were
ﬁxed with 4% paraformaldehyde, stained with crystal violet, and left
for drying. Furthermore, the images were captured. Scale bar: 200 μm.
(B) For wound healing assay, cells were wounded by scratching and
monitored over diﬀerent time intervals (24, 48, and 72 h) upon
treatment with 10 μM TA to observe the wound closure (40×)
magniﬁcation, scale bar: 400 μm. (C) Matrigel invasion assay was
performed on NSCLC cells A549 and H1299. The cells were treated
with TA at 20 μM for 24 h. Thereafter, the cells were washed with
PBS, ﬁxed with methanol, and stained using crystal violet. Upon
drying, images were taken. Scale bar: 200 μm.
23943
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Figure 4. Tannic acid interactive network analyses. Protein−protein interaction: an interactive protein−protein network of all 53 tannic acidregulated proteins. Color coding was done on the basis of the bottleneck rank of individual protein networks generated from Cytoscape. Most of
the proteins are found in various types of cancer groups. CTNNB1 and VEGFA are the top two identiﬁed main regulatory proteins in this
interactome.

presence and absence of TA treatment, in vitro angiogenesis
was performed on the HUVECs (Figure 6).
HUVEC tubular formation was suppressed by incubation
with the media conditioned with 10, 15, and 20 μM TA
(Figure 6A). The total length of tubules decreased with respect
to the increased concentrations of TA: 40.01 ± 2.37, 32.53 ±
4.50, and 19.22 ± 3.37% (Figure 6B). The control group was
HUVECs incubated with untreated media and was set as
100%, proposing that the TA treatment with 20 μM was able
to inhibit tube formation in HUVECs.
3.6. TA Signiﬁcantly Reduces VEGF Secretion by
NSCLC Cells. Angiogenesis occurs primarily due to the
production of excessive VEGF.5,43 Therefore, we sought to
investigate whether TA inhibits the secretion of VEGF using
ELISA (Figure 7).
The treatment of NSCLC cells with diﬀerent concentrations
of TA signiﬁcantly decreased the VEGF expression level in a
dose-dependent manner, suggesting that TA treatment has an
inhibitory eﬀect on the level of the VEGF produced. Indeed, as
the treatment continued with longer incubation, the level of
the VEGF also decreased accordingly in both cell lines. The
reduction in VEGF levels was statistically signiﬁcant.

accounting for 85 percent of all occurrences. Despite enormous
scientiﬁc investigations in lung cancer, the incidence and
fatality rates have not decreased signiﬁcantly.45 The presence
of increased angiogenesis in NSCLC has been linked to a bad
prognosis.46,47 Several angiogenic switch molecular mediators
are linked to a poor clinical outcome.48 Hence, antiangiogenesis therapy remains an attractive treatment option for
patients with NSCLC.49 In this study, we investigated a simple
yet clinically suitable natural molecule-based treatment
approach for NSCLC, which may augment the survival
outcome by inhibiting angiogenesis and decreasing the
systemic side eﬀect.
TA is a naturally occurring polyphenol molecule. The watersoluble polyphenols in TA attribute unique biological properties, which made it an excellent candidate for the medicinal
applications. Accumulating studies conﬁrmed TA as an
antimutagenic, antioxidant, and anticancer agent.19,24,50,51
Moreover, TA has been used for therapeutic purposes for
centuries.22 Notably, TA has become a very interesting topic in
anticancer drug discovery because of its economic and organic
production, in comparison to other chemical components.
Previous reports have shown anticancer potential in breast,
prostate cancer, and other cancers,17,29 but to the best of our
knowledge, its eﬀect on NSCLC due to the antiangiogenesis
eﬀect and downregulation of the VEGF signaling pathway has
not yet been studied.

4. DISCUSSION
Lung cancer is one of the most common cancers globally, both
in terms of incidence and mortality (18 percent of total cancer
deaths).44 NSCLC is the most common form of LC,
23944
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Figure 5. Molecular interaction of tannic acid and angiogenesis-related proteins. Figures were generated using Discovery Studio. (A) Interaction
between VEGFA (PDB ID: 5FV1) and tannic acid (PubChem CID: 16129778). Binding pattern of VEGFA and tannic acid docking done using
FireDock with −36.17 global binding energy. The amino acid residues of the binding pocket are THR 31, LEU 32, ASP 34, PHE 36, PRO 40, ARG
56, CYS 57, GLY 59, CYS 60, CYS 61, LEU 66, GLU 67, CYS 68, VAL 69, PRO 70, GLU 73, LEU 97, and HIS 99. (B) Molecular interaction
between CBP (PDB ID: 5J0D) and tannic acid (PubChem CID: 16129778). Binding pattern of CBP and tannic acid docking done using FireDock
with −34.24 global binding energy. The amino acid residues of the binding pocket are Leu1109, Arg1112, Gln1113, Pro1114, Val1115, Asp1116,
Leu1120, Gly1121, Ile1122, Tyr1167, Asn1168, Arg1169, Ser1172, Arg1173, and Val1174. (C) Molecular interaction between P300 (PDB ID:
6GYR) and tannic acid (PubChem CID: 16129778). Binding pattern of CBP and tannic acid docking done using FireDock with −59.99 global
binding energy. The amino acid residues of the binding pocket are Tyr1394, Ile1395, Ser1396, Tyr1397, Ile1435, Trp1436, Ala1437, Cys1438,
Pro1439, Pro1440, Ser1441, Glu1442, Asp1444, Tyr1446, Pro1460, Glu1505, Gly1506, Asp1507, Phe1508, Asn1511, Lys1590, His1591, Val1594,
and Arg1627.

consistent with the previous literature that have reported the
antitumoral and anticancer activity of TA on other types of
cancers such as prostate cancer,29,53 breast cancer,17,24 and
colon cancer.54
Angiogenesis occurs to build an intact network to circulate
nutrition and oxygen and is vital for cancer cells’ function,
growth, and survival. A high level of the VEGF is necessary for
this network, and if its function is hindered and could not keep
up with the rapid growth of the tumor, the cancerous cells have
no other option but to undergo apoptosis.6 Collective reports
show that a decreased level of the VEGF caused inhibition of
tumor growth and proliferation.9,55−57 We have measured the
VEGF protein concentrations by ELISA, and the respective
data revealed that the VEGF level of the supernatant
remarkedly decreased following TA treatment. A high amount
of VEGF is generated from cancer cells early in tumor-induced
angiogenesis, and it then binds to VEGFR2 on endothelial cells
to cause angiogenesis.58−60 Our results (Figures 6 and 7)

In our study, TA has shown a signiﬁcant anticancer eﬀect on
NSCLC cells. The quantiﬁcation of the proliferation of A549
and H1299 by cell viability studies showed that TA treatment
reduces the rate of the proliferations of both cell lines
drastically and inhibits the growth and suppresses the cell
viability of A549 and H1299 (Figure 1). Additionally, our
results showed that in the presence of TA, there is a signiﬁcant
decline in the number of colonies (Figure 2). It was noticed
that viable cells and colonies of H1299 were not as much as
those in A549 cells. This result suggests that H1299 cells are
more sensitive to TA treatment than A549 cells. Moreover,
there is an inhibitory eﬀect on the number of cells invaded and
migrated, on A549 and H1299 (Figure 3). The process of
wound healing predominantly regulates and promotes the
growth of malignant cells52 and migration of cancer cells; our
scratch assay results support that TA has an inhibitory eﬀect on
the mechanism that regulates wound healing, in a timedependent fashion in both cell lines. Our ﬁndings are
23945

https://doi.org/10.1021/acsomega.2c02727
ACS Omega 2022, 7, 23939−23949

ACS Omega

http://pubs.acs.org/journal/acsodf

Figure 6. Tannic acid treatments inhibit the tube formation abilities
of HUVECs. In vitro tube formation assay was performed to
determine the eﬀect of TA on HUVEC cells. (A) 1 × 104 cells/
well were seeded in Matrigel-coated 96-well plates followed by various
TA concentrations (10, 15, 20, and 30 μM). Morphology images of
vascular-like structures/networks were captured using an EVOS FL
imaging system, and a quantiﬁcation of three random regions was
assessed using ImageJ software using an angiogenesis analyzer. (B)
Bar graph representing the quantiﬁcation of three random regions
assessed using ImageJ software using an angiogenesis analyzer. Data
represent means ± SEM, n = 3. *p < 0.01, **p < 0.001.

Article

Figure 7. Tannic acid treatment signiﬁcantly lowers the VEGF
secretion from tumor cells. ELISA assay was performed to determine
the eﬀect of TA on the VEGF protein expression in (A) A549 and
H1299 (B) cells. The cells were treated with TA (5, 10, 20, and 30
μM) for 24, 48, and 72 h. The supernatant media were used to
measure the levels of VEGF secretion. Data represent means ± SEM,
n = 3. *p < 0.01, **p < 0.001.

suggest that such a decrease in VEGF secretion in NSCLC
when exposed to TA had attributed to the reduction of tube
formulation capability, hence leading to a decline in angiogenesis and formation of intact blood vasculature networks.
Inhibition of angiogenesis would potentially suppress the
metastasis and inhibit the chance of tumor cells spreading
around the patient’s body.
Overall, TA has an advantageous therapeutic proﬁle owing
to its safe and nontoxic plant-based nature, which makes it a
very suitable candidate for cancer therapy, especially for unﬁt
NSCLC patients. These results manifest that TA acts as a
potent inhibitor for blood vessel formation, hence strengthening the rationale of using TA as an antiangiogenic agent for
NSCLC therapy (Figure 8).
It is noteworthy to mention that additional in-depth studies
and in vivo studies would add more insights to the potential use
of TA as a new adjuvant treatment modality or a potential
preventive agent for NSCLC.

Figure 8. Schematic representation depicting the mechanism of
action of TA in NSCLC.

NSCLC therapy, either alone or in combination with other
anticancer drugs, to improve the patient’s quality of life by
reducing cancer therapy side eﬀects. The data also provide
support for that TA can be used as a preventive agent against
NSCLC.

5. CONCLUSIONS
This study demonstrates that TA inhibits angiogenesis via
decreasing the VEGF level and also suppressing the growth of
the NSCLC cells. TA treatment showed antitumor eﬀects
through various functional assays in NSCLC cells. Furthermore, the TA treatment strategy enhanced the antimetastatic
activity such as reduction in the cell migratory eﬀect and
invasion, in addition to signiﬁcant inhibition of the wound
healing process. We believe that these ﬁndings will pave the
way for the transfer of TA as a novel natural therapeutic for
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